Insmed announced five research abstracts accepted for presentation at the European Respiratory Society Congress 2026, showcasing data on its respiratory drugs. Highlights include Phase 3b ENCORE study results on ARIKAYCE for Mycobacterium avium complex lung infections and analyses of BRINSUPRI for non-cystic fibrosis bronchiectasis and treprostinil palmitil inhalation powder for pulmonary arterial hypertension. These findings support Insmed's efforts to improve treatment options for serious lung diseases. The presentations will provide insights into treatment efficacy, safety, and patient impact, potentially shaping future respiratory care.
SpaceX is set to attempt a key milestone with its Starship Flight Test 14, which AI analysis suggests could spark a significant stock rally of about 20%. The AI highlights that past flight successes and regulatory filings indicate strong progress, wh...
Chainlink's LINK token rose about 5%, trading near $11.68-$11.84, after announcing a partnership with fintech firm Bottomline to enable cross-chain, cross-border payments for over 600 banks. Additionally, Chainlink Data Feeds launched on the Tempo st...
Leonardo's first half results show improved growth quality with like-for-like sales up 8.2% and orders increasing by 39%. EBITA growth was driven more by margin expansion than volume increases. The company's backlog reached €52.6 billion, providing a...
Bitcoin surged almost 5% to surpass $81,000, boosting the total crypto market by about $112 billion to $2.7 trillion. This rally followed comments from Federal Reserve Governor Christopher Waller, who indicated support for holding interest rates stea...
Cardano's ADA token surged 12.54% to $0.2214 with a market cap of $8.12 billion, approaching a key resistance zone at $0.24–$0.25. Analyst 0xNeena highlighted that a breakout above this level could push ADA toward $0.30, $0.36, and $0.4368, signaling...
